SEARCH

SEARCH BY CITATION

References

  • 1
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378390.
  • 2
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646674.
  • 3
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:1185111858.
  • 4
    Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007;27:5576.
  • 5
    Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:42934300.
  • 6
    Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:2534.
  • 7
    Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315:971979.
  • 8
    Zhu AX, Duda DG, Sahani DV, Jain RK. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J 2009;15:263268.
  • 9
    Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009;10:794800.
  • 10
    Cheng A, Kang Y, Lin D, Park J, Kudo M, Qin S, et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011;29( suppl):abstract 4000.
  • 11
    Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011;17:19731983.
  • 12
    Finn RS, Kang YK, Mulcahy M, Polite BN, Lim HY, Walters I, et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012;18:20902098.
  • 13
    Llovet JM, Decaens T, Raoul J-L, et al. Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study. Program and abstracts of the 47th Annual Meeting of the European Association for the Study of the Liver; April 18–22,2012; Barcelona, Spain. Abstract 1398.
  • 14
    Bristol-Meyers Squibb. BRISK-FL study with investigational compound brivanib in hepatocellular carcinoma does not meet overall survival primary endpoint. http://news.bms.com/press-release/rd-news/brisk-fl-study-investigational-compound-brivanib-hepatocellular-carcinoma-does. Accessed on November 5, 2012.
  • 15
    Toh H, Chen P, Carr BI, Knox JJ, Gill S, Steinberg J, et al. A phase II study of ABT-869 in hepatocellular carcinoma (HCC): interim analysis. J Clin Oncol 2009;27( suppl):abstract 4581.
  • 16
    ClinicalTrials.gov. Efficacy and tolerability of ABT-869 versus sorafenib in advanced hepatocellular carcinoma (HCC). http://clinicaltrials.gov/ct2/show/NCT01009593. Accessed on November 5, 2012.
  • 17
    Zhu AX, Finn RS, Mulcahy MF, Gurtler JS, Sun W, Schwartz JD, et al. A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2010;28( suppl):abstract 4083.
  • 18
    Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:66576663.
  • 19
    Onyx Pharmaceuticals. Addition of Tarceva⌖ (erlotinib) to Nexavar⌖ (sorafenib) did not provide additional benefit to patients with unresectable liver cancer versus Nexavar alone in phase 3 trial. http://www.onyx.com/view.cfm/627/addition-of-tarceva-erlotinib-to-nexavar-sorafenib-did-not-provide-additional-benefit-to-patients-with-unresectable-liver-cancer-versus-nexavar-alone-in-phase-3-trial. Accessed on November 5, 2012.
  • 20
    Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843850.
  • 21
    ClinicalTrials.gov. Bevacizumab and erlotinib or sorafenib as first-line therapy in treating patients with advanced liver cancer. http://clinicaltrials.gov/ct2/show/NCT00881751. Accessed on November 5, 2012.
  • 22
    ClinicalTrials.gov. Erlotinib plus bevacizumab in hepatocellular carcinoma (HCC) as second-line therapy. http://clinicaltrials.gov/ct2/show/NCT01180959. Accessed on November 5, 2012.
  • 23
    Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424430.
  • 24
    Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 2011;117:50945102.
  • 25
    Rimassa L, Porta C, Borbath I, Daniele B, Salvagni S, Van Laethem JL, et al. Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: results of a randomized controlled phase II trial (RCT). J Clin Oncol 2012;30( suppl):abstract 4006.
  • 26
    Verslype C, Cohn AL, Kelley RK, Yang T-S, Su W-C, Ramies DA, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2012;30( suppl):abstract 4007.
  • 27
    Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010;304:21542160.